Multi‐parameter flow cytometric quantitation of the expression of the tumor‐associated antigen SM3 in normal and neoplastic ovarian tissues. A comparison with HMFG1 and HMFG2

No abstract is available for this paper.

• Publication year

  1991

• Venue

  Cancer

• Publication date

  1991-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/1097-0142(19910701)68:1<169::AID-CNCR2820680130>3.0.CO;2-RPMID 2049739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibody-Guided Irradiation of Malignant Lesions : Three Cases Illustrat ing a New Method of Treatment '

  2017cited by this paper
• Tissue preparation for simultaneous flow cytometric quantitation of tumour associated antigens and DNA in solid tumours.

  1990cited by this paper
• Radioimmunoscintigraphy of ovarian tumors using a new monoclonal antibody, SM-3.

  1990cited by this paper
• Flow cytometric detection of multifocal DNA aneuploid cell populations in mastectomy specimens containing a primary breast carcinoma.

  1990cited by this paper
• Flow cytometric quantitation of tumor-associated antigens in solid tumors.

  1990cited by this paper
• A core protein epitope of the polymorphic epithelial mucin detected by the monoclonal antibody SM‐3 is selectively exposed in a range of primary carcinomas

  1989cited by this paper
• Revised FIGO staging for gynaecological cancer

  1989cited by this paper
• Therapeutic considerations in the use of intraperitoneal radiolabelled monoclonal antibodies in ovarian carcinoma.

  1989cited by this paper
• A short sequence, within the amino acid tandem repeat of a cancer‐associated mucin, contains immunodominant epitopes

  1989cited by this paper
• Kinetics, quantitative analysis and radioimmunolocalization using indium-111-HMFG1 monoclonal antibody in patients with breast cancer.

  1989cited by this paper
• Clinical significance of abnormal nuclear DNA content in serous ovarian tumors

  1988cited by this paper
• Significance of multiparameter flow cytometric analysis of ovarian cancer.

  1988cited by this paper
• Immunoscintigraphy with 131I‐labelled monoclonal antibodies HMFG2 and HMFG1 F(ab')2 versus abdominal CT scan in the detection of residual disease in ovarian cancer patients

  1988cited by this paper
• Dual‐parameter flow cytometry of transitional cell carcinomas. Quantitation of DNA content and binding of carbohydrate ligands in cellular subpopulations

  1988cited by this paper
• Expression of CEA, CA125, CA19-9 and human milk fat globule membrane antigen in ovarian tumours.

  1988cited by this paper
• Antibody‐guided diagnosis and therapy of malignant lesions

  1988cited by this paper
• Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2----6 alpha-N-acetylgalactosaminyl (sialosyl-Tn) epitope.

  1988cited by this paper
• Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies.

  1988cited by this paper
• Quantitation of human milk fat globule (HMFG1) expression in breast carcinoma and its association with survival.

  1988cited by this paper
• Patterns of expression of a tumor associated antigen, defined by the monoclonal antibody HMFG2, in human epithelial ovarian carcinoma. Comparison with expression of the HMFG1, AUA1, and F36/22 antigens

  1987cited by this paper
• Quantitative pathology today--a technical view.

  1987cited by this paper
• Expression of Ha-ras oncogene p21 protein in relation to the cell cycle of cultured human tumor cells.

  1987cited by this paper
• Advances in flow cytometry for diagnostic pathology.

  1987cited by this paper
• Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin.

  1987cited by this paper
• Oncogene expression in ovarian cancer: a pilot study of c-myc oncoprotein in serous papillary ovarian cancer.

  1987cited by this paper
• Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies.

  1987cited by this paper
• A new immunoassay using monoclonal antibodies HMFG1 and HMFG2 together with an existing marker CA125 for the serological detection and management of epithelial ovarian cancer.

  1986cited by this paper
• Patterns of reaction of monoclonal antibodies HMFG-1 and -2 with benign breast tissues and breast carcinomas.

  1986cited by this paper
• A prospective study of 123I-labeled monoclonal antibody imaging in ovarian cancer.

  1986cited by this paper
• A simultaneous flow cytometric assay for c-myc oncoprotein and DNA in nuclei from paraffin embedded material.

  1985cited by this paper
• The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer.

  1985cited by this paper
• A method for improving light collection by 600% from square cross section flow cytometry chambers.

  1985cited by this paper
• Radioimmunodetection in patients with suspected ovarian cancer.

  1985cited by this paper
• A method for simultaneous nuclear immunofluorescence and DNA content quantitation using monoclonal antibodies and flow cytometry.

  1985cited by this paper
• Correlated measurements of DNA, RNA, and protein in individual cells by flow cytometry.

  1985cited by this paper
• The use of radiolabelled monoclonal antibodies to human milk fat globule membrane antigens in antibody-guided tumour imaging, and administration of therapeutic dose of labelled antibody in wide-spread ovarian carcinoma. A preliminary report.

  1985cited by this paper
• Expression of CA antigen on human urinary bladder tumors

  1985cited by this paper
• Ovarian cancer: diagnosis using 123I monoclonal antibody in comparison with surgical findings.

  1984cited by this paper
• Automated flow-cytometric identification of colo-rectal tumour cells by simultaneous DNA, CEA-antibody and cell volume measurements.

  1984cited by this paper
• The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas

  1984cited by this paper
• Complexity of expression of antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells.

  1983cited by this paper
• Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours.

  1982cited by this paper
• Differentiation antigens expressed by epithelial cells in the lactating breast are also detectable in breast cancers

  1981cited by this paper
• Dual laser beam focussing for flow cytometry through a single crossed cylindrical lens pair.

  1981cited by this paper
• Monoclonal antibodies to epithelium‐specific components of the human milk fat globule membrane: Production and reaction with cells in culture

  1981cited by this paper
• Tumors of the Ovary and Maldeveloped Gonads

  1981cited by this paper
• Letter: "Febrile convulsions".

  1973cited by this paper
• SALMONELLAS IN MEAT.

  1964cited by this paper

• IL-7 armed binary CAR T cell strategy to augment potency against solid tumors

  2025cites this paper
• IL-7 armed binary CAR T cell strategy to augment potency against solid tumors

  2025cites this paper
• The expansion of targetable biomarkers for CAR T cell therapy

  2018cites this paper
• The Clinical Significance of HPRT as a Diagnostic and Therapeutic Biomarker for Hematological and Solid Malignancies

  2018cites this paper
• CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation

  2018cites this paper
• Anti-MUC1 Nanobody Can Redirect T-Body Cytotoxic Effector Function

  2009cites this paper
• Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor1

  2008cites this paper
• Chimeric Antigen Receptor aTumor-Associated MUC 1 : The Evolution of Retargeting of Human T Cells to Burchell and

  2008cites this paper
• Consensus conference about imaging of Benign Prostatic Hypertrophy.

  2005cites this paper
• Limited tumor growth (HT29) in vivo under RO205-2349 is due to increased apoptosis and reduced cell volume but not to decreased proliferation rate.

  2004cites this paper
• Immunohistochemical Detection of the MUC1 Gene Product in Human Cancers Grown in scid Mice

  1998cites this paper
• Expression and loss of heterozygosity of c‐met proto‐oncogene in primary breast cancer

  1995cites this paper
• Potential for immunotherapy: PEM as a target antigen

  1995cites this paper
• Multiparameter flow cytometric measurement of epidermal growth factor receptor and c‐erbB‐2 oncoprotein in cultured cells and in fresh and preserved solid tumor cells

  1995cites this paper
• Peroperative radioimmunodetection of ovarian carcinoma using a hand-held gamma detection probe.

  1994cites this paper
• Humanization of an anti-mucin antibody for breast and ovarian cancer therapy.

  1994cites this paper
• Flow cytometric measurement of cell components other than DNA: virtues, limitations, and applications in gynecologic oncology.

  1992cites this paper
• Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erbB-2 oncoprotein in normal and neoplastic tissues of the female genital tract.

  1991cites this paper